NCT06546098 Molgramostim Nebulizer Solution Expanded Access Program Protocol Status AVAILABLE Phase N/A
NCT06431776 Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Status RECRUITING Phase PHASE3
NCT04544293 Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03597347 Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection Status TERMINATED Phase PHASE2
NCT03482752 Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Status TERMINATED Phase PHASE3
NCT03421743 Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection Status COMPLETED Phase PHASE2
NCT03181932 AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis Status COMPLETED Phase PHASE3
NCT02702180 Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis Status COMPLETED Phase PHASE2
NCT01746095 Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients Status COMPLETED Phase PHASE2
NCT01537666 Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics Status COMPLETED Phase PHASE1